Menaquinone-7 slows down progression of coronary artery calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery Calcification: A Randomized, Placebo-Controlled Trial,” were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection. The event was organized by the European Society of Hypertension (ESH), and held in Milan on May 23–26, 2025. The two-year intervention compared vitamin K2 supplementation with a placebo group.
What is VitaK-CAC?
The study, “Menaquinone-7 supplementation to reduce vascular calcification in patients with coronary artery disease (VitaK-CAC trial),” was designed to explore the protective effect of supplementation with vitamin K2 as MK-7, a Vitamin K homologue (menaquinone-7 as MenaQ7®), on slowing the progression of coronary artery calcification (CAC) from baseline CAC scores in symptomatic participants with coronary artery calcification, lending further understanding to the mechanism by which K2 inhibits calcification.
Primary outcomes presented
The first findings of this randomized, double-blind, placebo-controlled clinical trial were presented at the conference in Milan, showing that two years of MK-7 supplementation can slow the progression of CAC in participants with mild to moderate coronary artery calcification, irrespective of blood pressure status. The groups had similar baseline characteristics before supplementation, and follow-up captured changes in CAC scores, with no significant adverse effects observed, supporting a potentially beneficial effect — although the clinical significance requires further confirmation.
More to come
The VitaK-CAC Trial was initiated on the heels of the publication of the groundbreaking 3-year MenaQ7® cardiovascular study, but longer follow-up and full publication are still needed to assess effects on cardiovascular events and risk. The full results are expected to be published this year and presented at additional prestigious conferences and congresses, and the forthcoming paper should provide further evidence of the therapy and its potential for proactive cardiovascular health.
Discover MenaQ7®
MenaQ7® is the first and best clinically proven Vitamin K2 as MK-7 for bone and heart health. With 22+ clinical studies demonstrating safe, effective health benefits, MenaQ7® offers the highest quality and sustainability commitments, delivering the purest Vitamin K2 molecule derived from natural fermentation at our European manufacturing site.
Formulate even under the harshest conditions of supplement and food processing with MenaQ7® Matrix, the natural choice for stable and protected Vitamin K2.
MenaQ7®’s ironclad quality, science, and versatile portfolio provide you with flexibility and concept opportunities when developing your new product and give you the confidence that it will gain attention on crowded shelves.
